2023 - Research.com Best Female Scientist Award
2023 - Research.com Best Scientist Award
2022 - Research.com Best Female Scientist Award
2022 - Research.com Best Scientist Award
2013 - Member of the National Academy of Medicine (NAM)
Her main research concerns Breast cancer, Cancer, Internal medicine, Oncology and Ovarian cancer. Judy Garber interconnects Germline mutation, Gynecology, Cancer research and Risk factor in the investigation of issues within Breast cancer. Her Cancer research integrates issues from Odds ratio, Bioinformatics, Genetic testing and Medical genetics.
Her research investigates the connection between Internal medicine and topics such as Gene mutation that intersect with issues in Estrogen receptor. Her Oncology study integrates concerns from other disciplines, such as BRCA2 Protein, Li–Fraumeni syndrome, Pathology, Tamoxifen and Triple-negative breast cancer. Her research in Ovarian cancer focuses on subjects like Fallopian tube, which are connected to Serous Tubal Intraepithelial Carcinoma and Serous carcinoma.
Judy Garber mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Genetic testing. Her biological study spans a wide range of topics, including Germline mutation, Cancer research, Gynecology, Ovarian cancer and Family history. Her Internal medicine research is multidisciplinary, incorporating elements of Li–Fraumeni syndrome and Pathology.
Her Oncology research incorporates elements of Chemotherapy, Phases of clinical research, Germline, Tamoxifen and Triple-negative breast cancer. Her Cancer research is multidisciplinary, incorporating perspectives in Mutation and Bioinformatics. The various areas that Judy Garber examines in her Genetic testing study include Genetic counseling and Family medicine.
Judy Garber mainly investigates Breast cancer, Internal medicine, Oncology, Cancer and Germline. Her research in Breast cancer intersects with topics in Placebo and Cancer research. Her Internal medicine study frequently links to adjacent areas such as Polygenic risk score.
Her Oncology research incorporates themes from Odds ratio, Pancreatic cancer, CHEK2, PALB2 and Ovarian cancer. Her Cancer research includes elements of Phenotype, Disease and Li–Fraumeni syndrome. Her work carried out in the field of Genetic testing brings together such families of science as Genetic counseling and Family medicine.
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Cancer research. Her Breast cancer study combines topics from a wide range of disciplines, such as CHEK2, Germline and Immunohistochemistry. Her studies examine the connections between Internal medicine and genetics, as well as such issues in Human genetics, with regards to Heterozygote advantage and Missense mutation.
Her Oncology research incorporates themes from Odds ratio, Cohort study, Ovarian cancer, Penetrance and Genetic testing. The study incorporates disciplines such as Phenotype, Disease, Clinical genomics, Research center and Subject in addition to Cancer. Her Cancer research study integrates concerns from other disciplines, such as Olaparib, PARP inhibitor and Estrogen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer.
Richard Fishel;Mary Kay Lescoe;M.R.S. Rao;Neal G. Copeland.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek.
The Lancet (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
A Tutt;M Robson;J E Garber;S M Domchek.
The Lancet (2010)
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Timothy R. Rebbeck;Henry T. Lynch;Susan L. Neuhausen;Steven A. Narod.
The New England Journal of Medicine (2002)
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik-Zainal;Ludmil B. Alexandrov;David C. Wedge;Peter Van Loo;Peter Van Loo;Peter Van Loo.
Molecular Definition of Breast Tumor Heterogeneity
Michail Shipitsin;Lauren L. Campbell;Pedram Argani;Stanislawa Weremowicz.
Cancer Cell (2007)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek;Tara M. Friebel;Christian F. Singer;D. Gareth Evans.
Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
Timothy R. Rebbeck;Tara Friebel;Henry T. Lynch;Susan L. Neuhausen.
Journal of Clinical Oncology (2004)
Recommendations for follow-up care of individuals with an inherited predisposition to Cancer. II. BRCA1 and BRCA2
Wylie Burke;Mary Daly;Judy Garber;Jeffrey Botkin.
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver;Andrea L. Richardson;Aron C. Eklund;Zhigang C. Wang.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: